Options trading strategies on Pfizer: Two tactics emerge from the market anomaly

In the Pfizer (PFE) options market, a rare and significant event has occurred that reveals noteworthy trading opportunities. The $29 put expiring on March 20 experienced extraordinary activity, with a volume/open interest (Vol/OI) ratio of 210.16, far surpassing the next most active trade on Alphabet (GOOG) by 35%. Properly decoded, these market signals can guide traders toward well-structured options strategies.

Pfizer presents an intriguing context for options analysis: once a COVID-19 demand beneficiary, the stock has undergone a dramatic 59% decline from its 2021 peak of $61.71, currently trading at $25.43. This environment of reduced volatility and sharp re-pricing creates unique conditions for those who can recognize hidden opportunities in the vol/OI data.

When Anomalous Volume Reveals Opportunities: Pfizer Data Analysis

The anomaly in Pfizer’s options market warrants careful examination. The $29 put expiring on March 20 saw 30,263 contracts traded against an open interest of just 144, indicating a concentration of volume rarely seen in large-cap stocks ($144 billion market cap).

Interestingly, the $29 call with the same expiration also recorded comparable volume, suggesting an intent to build volatility positions on both sides of the strike. On average, Pfizer’s 30-day options volume is 142,695 contracts; recent activity has been 1.39 times higher, marking the busiest day since December 17. Still, it’s below the quarterly peak of 890,898 contracts on November 4, right after Q3 2025 earnings were released.

A key catalyst was the December 16 update, when Pfizer reaffirmed 2025 guidance but cut 2026 outlooks: adjusted EPS estimated at $2.90 (median), down from $3.08 in 2025. This uncertainty about future earnings increased implied volatility, creating ideal conditions for strategies that capitalize on price swings.

The Long Straddle: Profit from Volatility with Bilateral Protection

The first strategy emerging from this anomaly is the Long Straddle, constructed simultaneously with the $29 put and call expiring on March 20. This options trading approach is designed for those expecting significant movement without certainty about direction—exactly what Pfizer’s scenario suggests.

The net debit for this trade is $4.38 per share ($438 per contract). Break-even points are at $33.38 on the upside and $24.62 on the downside. With 71 days remaining until expiration (notable considering we are only 9 days from March 20, as of March 11, 2026), time decay is not yet the dominant factor but will become increasingly important.

The probability of profit is estimated around 37%, with a 38.1% chance the stock closes beyond the breakeven points. While seemingly modest, the potential return compensates: if the stock moves downward following historical volatility ($1.76 expected move), it would close at $23.53. Although only 3.6% below the breakeven of $24.62, the gross profit would be $89 per share—equivalent to an annualized return of 128% [$109 / $438 * 365 / 71].

The Long Straddle is especially suitable for traders aiming to leverage volatility without directional bias. Time works slightly against this position (71 days), but this window still allows significant movement before accelerated deterioration in the final month.

The Bull Put Spread: Minimize Risk with a Bullish Operation

The second options trading tactic visible in the Vol/OI data is the Bull Put Spread, a more conservative structure for those anticipating a modest rebound in prices.

This strategy involves selling the $29 put (collecting a premium of $390) and simultaneously buying protection with a $26 put (costing $156). The net credit is $234. The maximum theoretical loss is limited to $66, offering a favorable risk/reward ratio of 0.28:1—risking $28 for every $100 of potential gain.

If Pfizer closes above $29 at expiration (March 20), the trader realizes the full profit of $234, representing a 354.55% return, or an annualized rate of 1,848.73%. Although the success probability is roughly one in three, the breakeven is at $26.66, only 4.84% above the current price of $25.43. Given the expected move of 6.96% in either direction, there is a reasonable margin of safety.

Additionally, profits are possible if the stock ends between $26.66 and $29, providing a broader profit zone than the Long Straddle.

Which Options Strategy to Choose? Final Comparison

Both strategies stem from the anomalous volume data but serve different trader profiles.

Long Straddle is suitable for those who:

• Expect significant movement but are uncertain about direction
• Accept moderate success probabilities (37%) for high potential gains
• Tolerate time decay over the remaining 71 days
• Have sufficient capital to cover the $438 net debit per contract

Bull Put Spread is preferable for traders who:

• Maintain a slightly bullish outlook on Pfizer
• Want to limit maximum risk (loss capped at $66)
• Seek an exceptional annualized return despite modest probabilities
• Have experience managing short positions and margin requirements

For average traders, the Bull Put Spread offers a more controlled risk/reward profile, with predictable maximum loss. However, it requires active management as expiration approaches on March 20.

In both cases, Pfizer’s environment—characterized by volatility, sharp re-pricing, and earnings uncertainty for 2026—provides an ideal substrate for options strategies that exploit these market fractures. The key is recognizing when anomalous vol/OI data signals genuine opportunities rather than noise.